scholarly journals Essential Amino Acid Supplement Lowers Intrahepatic Lipid despite Excess Alcohol Consumption

2019 ◽  
Author(s):  
Melynda S. Coker ◽  
Kaylee Ladd ◽  
Josh Kim ◽  
Carl J. Murphy ◽  
Ryan DeCort ◽  
...  
Keyword(s):  
Body Composition ◽  
Amino Acid ◽  
Alcohol Consumption ◽  
Essential Amino Acid ◽  
Blood Lipids ◽  
High Dose ◽  
Amino Acid Supplement ◽  
Acid Supplement ◽  
Intrahepatic Lipid ◽  
Excess Alcohol Consumption

Excess alcohol consumption is a top risk factor for death and disability. Fatty liver will likely develop and the risk of liver disease increases. We have previously demonstrated that an essential amino acid supplement (EAAS) improved protein synthesis and reduced intrahepatic lipid in the elderly. The purpose of this study was to further evaluate the influence of EAAS on intrahepatic lipid (IHL), body composition, and blood lipids in individuals with mild to moderate alcohol use disorder (AUD). Following consent, determination of eligibility, and medical screening, 25 participants (18 males at 38±15 years/age and 7 females at 34±18 years/age) were enrolled and randomly assigned to one of two dosages: a low dose (LD: 8 grams of EAAS twice/day (BID)) or high dose (HD: 13 grams of EAAS BID). Both groups consumed the supplement for 4 weeks. Pre- and post-EAAS administration, IHL was determined using magnetic resonance imaging/spectroscopy, body composition was analyzed using dual energy x-ray absorptiometry, and blood parameters were measured by LabCorp. T-tests were used for statistical analysis and considered significant at P<0.05. While there was no significant change in IHL in the LD group, there was a significant 23% reduction in IHL in the HD group (p=0.02). Fat mass, lean tissue mass, bone mineral content, and blood lipids were not altered. Post-EAAS phosphatidylethanol was elevated and remained unchanged in LD at 407±141 ng/ml and HD at 429±196 ng/ml, indicating chronic and excess alcohol consumption. Based on these results, we conclude that 13 grams of proprietary EAAS consumed BID lowers IHL in individuals with mild to moderate AUD.

scholarly journals Essential Amino Acid Supplement Lowers Intrahepatic Lipid despite Excess Alcohol Consumption

Nutrients ◽  
2020 ◽  
Vol 12 (1) ◽  
pp. 254
Author(s):  
Melynda S. Coker ◽  
Kaylee R. Ladd ◽  
Jimin Kim ◽  
Carl J. Murphy ◽  
Ryan DeCort ◽  
...  
Keyword(s):  
Body Composition ◽  
Amino Acid ◽  
Alcohol Consumption ◽  
Essential Amino Acid ◽  
Blood Lipids ◽  
High Dose ◽  
Amino Acid Supplement ◽  
Acid Supplement ◽  
Intrahepatic Lipid ◽  
Excess Alcohol Consumption

Excess alcohol consumption is a top risk factor for death and disability. Fatty liver will likely develop and the risk of liver disease increases. We have previously demonstrated that an essential amino acid supplement (EAAS) improved protein synthesis and reduced intrahepatic lipid in the elderly. The purpose of this exploratory pilot study was to initiate the evaluation of EAAS on intrahepatic lipid (IHL), body composition, and blood lipids in individuals with mild to moderate alcohol use disorder (AUD). Following consent, determination of eligibility, and medical screening, 25 participants (18 males at 38 ± 15 years/age and 7 females at 34 ± 18 years/age) were enrolled and randomly assigned to one of two dosages: a low dose (LD: 8 g of EAAS twice/day (BID)) or high dose (HD: 13 g of EAAS BID). Five of the twenty-five enrolled participants dropped out of the intervention. Both groups consumed the supplement BID for 4 weeks. Pre- and post-EAAS administration, IHL was determined using magnetic resonance imaging/spectroscopy, body composition was analyzed using dual-energy X-ray absorptiometry, and blood parameters were measured by LabCorp. T-tests were used for statistical analysis and considered significant at p < 0.05. While there was no significant change in IHL in the LD group, there was a significant 23% reduction in IHL in the HD group (p = 0.02). Fat mass, lean tissue mass, bone mineral content, and blood lipids were not altered. Post-EAAS phosphatidylethanol was elevated and remained unchanged in LD at 407 ± 141 ng/mL and HD at 429 ± 196 ng/mL, indicating chronic and excess alcohol consumption. The HD of the proprietary EAAS formulation consumed BID seemed to lower IHL in individuals with mild to moderate AUD. We suggest that further studies in a larger cohort be conducted to more completely address this important area of investigation.

Essential Amino Acid Supplement lowers Intrahepatic Lipid in Individuals with Alcohol Use Disorder

2020 ◽  
Vol 34 (S1) ◽  
pp. 1-1
Author(s):  
Melynda S. Coker ◽  
Kaylee Ladd ◽  
Josh Kim ◽  
Carl J. Murphy ◽  
Ryan DeCort ◽  
...  
Keyword(s):  
Amino Acid ◽  
Alcohol Use ◽  
Essential Amino Acid ◽  
Alcohol Use Disorder ◽  
Amino Acid Supplement ◽  
Acid Supplement ◽  
Intrahepatic Lipid

scholarly journals Progression of chronic renal failure on substituting a ketoacid supplement for an amino acid supplement.

1992 ◽  
Vol 2 (7) ◽  
pp. 1178-1185 ◽  
Author(s):  
M Walser ◽  
S Hill ◽  
L Ward
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Amino Acid ◽  
Essential Amino Acid ◽  
Plasma Lipids ◽  
Urinary Cortisol ◽  
Amino Acid Supplement ◽  
Low Protein ◽  
Acid Supplement ◽  
Low Phosphorus

Twelve patients with severe chronic renal failure (average initial GFR, 13 mL/min) were monitored for 4 to 23 months while receiving an essential amino acid supplement and were then switched to a ketoacid supplement for 6 to 40 months, while continuously receiving a very low-protein (0.3 g/kg), low-phosphorus (7 to 9 mg/kg) diet. Urinary urea N excretion indicated that actual dietary protein intake averaged 0.46 g/kg. Progression, estimated as the linear regression slope of radioisotopically determined GFR on time, slowed from -0.46 +/- 0.31 (SD) to -0.24 +/- 0.15 mL/min/month (P = 0.029). Serum urea N, creatinine, phosphate, and uric acid rose significantly as GFR fell; blood pressure, plasma lipids, and urinary urea excretion were unchanged. Urinary 17-hydroxy-corticosteroid excretion decreased 18%, but this change was only marginally significant (P = 0.087). There was no change in plasma or urinary cortisol or urinary aldosterone. Viewed in light of previous evidence that progression seldom slows when treatment remains constant, the results suggest that this ketoacid supplement slows progression by approximately half, compared with an essential amino acid supplement, with no change in diet.

Sign in / Sign up

Export Citation Format

Share Document